Vera Salus Ricerca has successfully completed a 1-year training at BioArk (Switzerland) aimed at polishing the business developmental plans of FlavOncology, its proprietary drug platform for the cure of cancer patients.

During 2020, Vera Salus Ricerca Srl (VSR) has performed a Pre-incubation Program at BioArk (Valais, Switzerland) sponsored by the Ark Foundation, which included professional training and coaching to optimize business and operational plans toward FlavOncology’s industrial development. FlavOncology is a versatile, small-molecule dug platform intended for the cure of patients with a variety of cancer types. The Ark’s program was successfully completed by VSR with the detailed definitions of strategies, goals and plans instrumental for fundraising launch and developmental achievements of FlavOncology.